China Focused Company - GNI Group (TSE: 2160) - Potential of F647 (Pirfenidone) in China
GNI Group (TSE: 2160) company whose major focus is on the Chinese market through Shanghai Genomics (100% ownership), and Beijing Continent (51% ownership). China’s market for IPF is GNI’s focus and at the current valuation (if convinced about the market size) it could present an investment opportunity. China regulatory approval of F647’s manufacturing facility and launch timeline are uncertain, and the report focuses mainly on product’s effectiveness, physicians’ feedback, the competitive landscape and our estimates of the Chinese market for IPF.
COMPANIES MENTIONED
GNI Group (TSE: 2160)
GNI Group (TSE: 2160)
